| Filed On | Filing |
|---|---|
| 12 Aug 2024 |
8-K/A: Results of Operations and Financial Condition
Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trials |
| 17 Jan 2024 |
8-K/A: Financial Statements and Exhibits
Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. |
| 21 Apr 2023 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying balance sheets of Viewpoint Molecular Targeting, Inc. (the “Company”) as of December 31, 2022 and 2021, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years t... |
| 23 Jan 2017 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 16 May 2014 | 8-K/A: Submission of Matters to a Vote of Security Holders |
| 24 Mar 2014 | 8-K/A: Financial Statements and Exhibits |
| 21 Mar 2013 | 8-K/A: Entry into a Material Definitive Agreement |
| 17 Jul 2012 | 8-K/A: Financial Statements and Exhibits |
| 19 Aug 2011 | 8-K/A: Entry into a Material Definitive Agreement |
| 24 Nov 2010 | 8-K/A: Financial Statements and Exhibits |
| 02 May 2006 | 8-K/A: Entry into a Material Definitive Agreement |
| 15 Aug 2005 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 24 Oct 1996 | 8-K/A: Changes in Registrant's Certifying Accountant |
Loading...
